TPST: tempesttx.com Company Buyout Price

Brandmark of Tempest Therapeutics (TPST)

Financial quote visualization for Tempest Therapeutics (TPST), which focuses on oncology therapies, shows an Enterprise Value of 15.41. To ensure test reliability, the company invests in costly temperature-controlled drug transportation. Its environmental development vector involves reducing harmful emissions during drug synthesis and maintaining an ethical approach to research. Stable management with deep expertise is preparing the business for collaboration with industry behemoths.

TPST Tempest Tx: Enterprise Value in the range 11/23/2025 - 10/28/2026

TPST (Tempest Therapeutics): analytical breakdowns and indicator data

- price and consensus price forecast:
Quote Chart Tempest Therapeutics Inc|TPST - Price Target Chart
- market capitalization data:
Market Capitalization Tempest Therapeutics|TPST - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Tempest Therapeutics|TPST - Book Capitalization|Market Cap to Net Assets Ratio tempesttx.com|TPST - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Tempest Therapeutics|TPST - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio tempesttx.com|TPST - Company Aggregate Debts|Debt to Book Value Tempest Therapeutics
Fundamental company valuation:TPST (Tempest Therapeutics Inc)
Manufactured products of Tempest Therapeutics Inc

The enterprise value of Tempest Therapeutics (TPST) reflects the total acquisition cost of the business, accounting for net debt. This EV chart aggregates market capitalization and liabilities, minus existing cash reserves. This metric allows for an assessment of the asset's real value beyond its equity. For a biotech firm with high R&D expenditures, this indicator is critical. The value trend highlights the company's financial vulnerability in the event of a potential failure of its oncology drug clinical trials.

Direct competitors

BeiGene Ltd. - Full Business Value|Total Company Value HALO (Halozyme Inc.)|Revolution Medicines Corp (RVMD) - Company Buyout Price|AAPG - Real Price to Acquire Entire Company|cgoncology.com (CGON) - Aggregate Business Value|Enterprise Value URGN|Real Price to Acquire Entire Company Bicara Therapeutics Inc|Enterprise Value PSNL|Enterprise Value ERAS (Erasca Oncology)|DCTH - Total Company Value|Business Value ymabs.com YMAB|AURA: Enterprise Value|CADL - Real Price to Acquire Entire Company|Enterprise Value ARAY|SLS (SELLAS Life Sciences Group) - Total Enterprise Value|ACTU - Total Company Value|Value Adjusted for Debt and Cash citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Enterprise Value|WHWK - Real Price to Acquire Entire Company|TScan - Real Price to Acquire Entire Company|CSBR: Enterprise Value|Total Company Value xbiotech.com XBIT|CEL-SCI (CVM) - Value Adjusted for Debt and Cash|Enterprise Value OSTX (OS Therapies Inc)|Total Enterprise Value radiopharmtheranostics.com (RADX)|Real Price to Acquire Entire Company Artiva Biotherapeutics, Inc.|Aggregate Business Value adlainortye.com (ANL)|VERU: Enterprise Value|Xilio Therapeutics Inc - Total Enterprise Value|RENB: Total Company Value|MURA: Real Price to Acquire Entire Company|Total Company Value kairospharma.com (KAPA)|OnKure Therapeutics (OKUR) - Full Business Value|Enterprise Value GDTC (CytoMed Therapeutics Ltd)|Total Enterprise Value CRIS|APLM (Apollomics, Inc.) - Total Company Value|Company Buyout Price Tharimmune Corporation THAR|Real Price to Acquire Entire Company Advanced Biomed (ADVB)|GNPX - Aggregate Business Value|Real Price to Acquire Entire Company Calidi Bio (CLDI)|sunshinebiopharma.com (SBFM) - Value Adjusted for Debt and Cash|XBIO - Real Price to Acquire Entire Company|Salarius Pharma (SLRX) - Aggregate Business Value|PPBT - Enterprise Value|Value Adjusted for Debt and Cash AON|BeiGene - Enterprise Value|Total Enterprise Value CKPT (Checkpoint Therapeutics Inc.)|Total Company Value Elevation Oncology|Value Adjusted for Debt and Cash iCAD Inc. ICAD|Ikena - Enterprise Value|NTBL: Enterprise Value|Total Company Value viracta.com (VIRX)|MorphoSys Inc (MOR) - Full Business Value|Enterprise Value NAYA (NAYA Bio)|Total Enterprise Value Ascentage (AAPGV)